<SEC-DOCUMENT>0001213900-25-125374-index.html : 20251223 <SEC-HEADER>0001213900-25-125374.hdr.sgml : 20251223 <ACCEPTANCE-DATETIME>20251223163704 ACCESSION NUMBER: 0001213900-25-125374 CONFORMED SUBMISSION TYPE: F-3 PUBLIC DOCUMENT COUNT: 18 FILED AS OF DATE: 20251223 DATE AS OF CHANGE: 20251223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Enlivex Therapeutics Ltd. CENTRAL INDEX KEY: 0001596812 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: F-3 SEC ACT: 1933 Act SEC FILE NUMBER: 333-292417 FILM NUMBER: 251601191 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 37 DEREH MENACHEM BEGIN ST. STREET 2: 15TH FLOOR CITY: TEL AVIV PROVINCE COUNTRY: L3 BUSINESS PHONE: 972 (0) 3 7326616 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 37 DEREH MENACHEM BEGIN ST. STREET 2: 15TH FLOOR CITY: TEL AVIV PROVINCE COUNTRY: L3 FORMER COMPANY: FORMER CONFORMED NAME: Bioblast Pharma Ltd. DATE OF NAME CHANGE: 20160919 FORMER COMPANY: FORMER CONFORMED NAME: BIO BLAST PHARMA LTD. DATE OF NAME CHANGE: 20140113 </SEC-HEADER> <DOCUMENT> <TYPE>F-3 <SEQUENCE>1 <FILENAME>ea0270663-f3_enlivex.htm <DESCRIPTION>REGISTRATION STATEMENT <TEXT> Document 1 - file: ea0270663-f3_enlivex.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-4.1 <SEQUENCE>2 <FILENAME>ea027066301ex4-1_enlivex.htm <DESCRIPTION>AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF THE COMPANY (AS AMENDED THROUGH NOVEMBER 17, 2025) <TEXT> Document 2 - file: ea027066301ex4-1_enlivex.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-5.1 <SEQUENCE>3 <FILENAME>ea027066301ex5-1_enlivex.htm <DESCRIPTION>OPINION OF FISCHER (FBC & CO.) <TEXT> Document 3 - file: ea027066301ex5-1_enlivex.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-23.1 <SEQUENCE>4 <FILENAME>ea027066301ex23-1_enlivex.htm <DESCRIPTION>CONSENT OF YAREL + PARTNERS, INDEPENDENT REGISTERED CERTIFIED PUBLIC ACCOUNTING FIRM <TEXT> Document 4 - file: ea027066301ex23-1_enlivex.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-FILING FEES <SEQUENCE>5 <FILENAME>ea027066301ex-fee_enlivex.htm <DESCRIPTION>FILING FEE TABLE <TEXT> Document 5 - file: ea027066301ex-fee_enlivex.htm
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>6 <FILENAME>image_001.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 6 - file: image_001.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>7 <FILENAME>ex5-1_001.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 7 - file: ex5-1_001.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>8 <FILENAME>ex23-1_001.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 8 - file: ex23-1_001.jpg
</DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>10 <FILENAME>R1.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> Document 10 - file: R1.htm
</DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>11 <FILENAME>R2.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> Document 11 - file: R2.htm
</DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>12 <FILENAME>R3.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> Document 12 - file: R3.htm
</DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>13 <FILENAME>Show.js <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> Document 13 - file: Show.js
</DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>14 <FILENAME>report.css <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> Document 14 - file: report.css
</DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>16 <FILENAME>FilingSummary.xml <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> Document 16 - file: FilingSummary.html
Document 16 - RAW XML: FilingSummary.xml
</DOCUMENT> <DOCUMENT> <TYPE>JSON <SEQUENCE>18 <FILENAME>MetaLinks.json <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> Document 18 - file: MetaLinks.json
</DOCUMENT> <DOCUMENT> <TYPE>ZIP <SEQUENCE>19 <FILENAME>0001213900-25-125374-xbrl.zip <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> Document 19 - file: 0001213900-25-125374-xbrl.zip
</DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>20 <FILENAME>ea027066301ex-fee_enlivex_htm.xml <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> Document 20 - file: ea027066301ex-fee_enlivex_htm.html
Document 20 - RAW XML: ea027066301ex-fee_enlivex_htm.xml
</DOCUMENT> </SEC-DOCUMENT>